SCHEMBL5998972

SCHEMBL5998972

CC(=O)Oc1c(C)c(C)c2c(c1C)C=CC(C)(C)O2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.42
CYP3A4 P08684 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
PDE4A P27815 1/20 0.40
PDE3A Q14432 1/20 0.40
PTPN1 P18031 1/20 0.39
ALOX5 P09917 2/20 0.39
PTGES O14684 1/20 0.39
KDM4E B2RXH2 1/20 0.38
CASP1 P29466 1/20 0.38
CASP7 P55210 1/20 0.38
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA7 P43166 1/20 0.36
CA9 Q16790 1/20 0.36
TTPA P49638 2/20 0.36
HIF1A Q16665 4/20 0.36
PDE4D Q08499 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9268369 0.84 MEN1 (0.38) ALDH1A1CYP3A4MEN1KMT2APDE4A
SCHEMBL9281491 0.84 MEN1 (0.38) ALDH1A1CYP3A4MEN1KMT2APDE4A
SCHEMBL9267968 0.83 MEN1 (0.37) CYP3A4MEN1KMT2APDE4APDE3A
SCHEMBL9274660 0.82 IDO1 (0.44) ALDH1A1MEN1KMT2APDE4APDE3A
SCHEMBL8488075 0.82 MEN1 (0.39) ALDH1A1CYP3A4MEN1KMT2APDE4A
SCHEMBL9272154 0.81 MEN1 (0.38) ALDH1A1CYP3A4MEN1KMT2APDE4A
SCHEMBL10447273 0.80 ACE2 (0.40) ALDH1A1CYP3A4MEN1KMT2APDE4A
SCHEMBL16529641 0.74 MEN1 (0.61) MEN1KMT2APDE4APDE3APTPN1
SCHEMBL16529493 0.74 MEN1 (0.61) MEN1KMT2APDE4APDE3APTPN1
SCHEMBL16530184 0.74 MEN1 (0.61) MEN1KMT2APDE4APDE3APTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105473567-B Formation of chromanes and chromenes by using silver (I) or gold (I) salts or complexes 帝斯曼知识产权资产管理有限公司 2020-07-31 CN disclosed
EP-3039017-B1 FORMATION OF CHROMANES AND CHROMENES BY USING SILVER(I) OR GOLD(I) SALTS OR COMPLEXES DSM IP ASSETS BV (NL) 2019-01-09 EP disclosed
EP-3039017-A1 FORMATION OF CHROMANES AND CHROMENES BY USING SILVER(I) OR GOLD(I) SALTS OR COMPLEXES DSM IP Assets B.V. (NL) 2016-07-06 EP disclosed
CN-105473567-A Formation of chromanes and chromenes by using silver(i) or gold(i) salts or complexes DSM IP ASSETS BV 2016-04-06 CN disclosed
WO-2015028463-A1 FORMATION OF CHROMANES AND CHROMENES BY USING SILVER(I) OR GOLD(I) SALTS OR COMPLEXES DSM IP ASSETS B.V. (NL) 2015-03-05 WO disclosed
EP-2842951-A1 Formation of chromanes and chromenes by using silver(I) or gold(I) salts or complexes DSM IP Assets B.V. (NL) 2015-03-04 EP disclosed
CN-101128423-A Novel lipoxygenase inhibitors LILLY CO ELI (US) 2008-02-20 CN disclosed
US-20060193797-A1 Chroman derivatives as lipoxygenase inhibitors GALILEO PHARMACEUTICALS, INC 2006-08-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060193797-A1 Chroman derivatives as lipoxygenase inhibitors NR0B1, ALOX5, ALOX15B ALDH1A1 757/4885CYP3A4 255/4885MEN1 4700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.